THE SHIELD | PART FOUR OF FOUR

The Architecture

The ruling did not happen on June 25, 2026. It was finished on June 25, 2026. Here is how it was built.

In Part Three of this series, we examined what the EPA determination at the centre of the Supreme Court ruling is actually worth, and what a federal appeals court already found when it looked closely at how the agency arrived at it. The answer was not reassuring. And nobody fixed it before it became the foundation of a seven-to-two Supreme Court decision that closed the courthouse door on more than 100,000 plaintiffs.

Part Three ended with a question: what does accountability look like when the courtroom is no longer an option?

Before answering that, it is worth understanding precisely how the courtroom was closed. Because it did not happen in a single Supreme Court ruling. It was constructed, track by track, over years. And the construction tells you something important about what it will take to build accountability in the other direction.

The Map

Six tracks. Each one a separate move. Each one pointing the same direction.

Track One: The Supreme Court argument.

Bayer’s preemption argument did not emerge fully formed. It was developed and refined through years of lower court litigation, tested in appellate courts, and finally carried to the Supreme Court in the Durnell case. The legal theory -- that FIFRA’s uniformity clause shields manufacturers from state failure-to-warn claims when the EPA has approved their label -- was Bayer’s highest-risk, highest-reward play. A loss would have meant the scientific debate continuing in trial courts indefinitely. A win, as the seven-to-two ruling demonstrated, meant the debate ending as a practical matter of law regardless of what the science eventually showed.

Track Two: The settlement as deadline pressure.

The $7.25 billion class settlement proposed in February 2026 was not simply a compensation mechanism. It was a timing instrument. With SCOTUS oral arguments set for April 27 and the opt-out deadline set for June 4, plaintiffs had to decide whether to accept the settlement before the Supreme Court ruled. Bayer needed that uncertainty hanging over claimants through the entire decision window. A SCOTUS win would dramatically reduce future liability; accepting the settlement before that win meant accepting less. Bayer structured the timeline to exploit that gap. Fourteen law firms representing nearly 20,000 claimants called the 600-page settlement agreement negotiated behind closed doors, handed to opposing counsel on announcement day, with fifteen days before Bayer sought preliminary approval. That is not how fair settlements are built. That is how you manufacture consent under a deadline.

Track Three: State shield laws.

While the federal legal strategy moved through the courts, Bayer was simultaneously running a state legislative campaign through a coalition called the Modern Ag Alliance. The alliance backed bills in multiple states declaring that a federally approved pesticide label satisfies any state-level duty to warn. North Dakota and Georgia passed such laws in 2025. In early 2026, Kentucky’s Republican-led legislature overrode Democratic Governor Andy Beshear’s veto to enact a version of the same law. Beshear, a former state attorney general, pointed out that cosmetics, personal hygiene products, and household cleaners all carry warning labels. Kentucky’s law would allow dangerous pesticides to be sold without any equivalent risk warnings. The legislature overrode him anyway. Three states with legislative shields in place before the SCOTUS ruling even landed.

Track Four: The executive order.

In early 2026, the Trump administration issued an executive order expanding domestic glyphosate production while offering liability protection to manufacturers. The order was framed as a national security and food independence measure. Most glyphosate is produced by Bayer in Germany and Syngenta in China; bringing production onshore, the administration argued, required legal protection because companies would otherwise face billions in potential lawsuits. Robert F. Kennedy Jr., HHS Secretary, defended the order. This is the same Robert F. Kennedy Jr. who represented Dewayne Johnson, the California groundskeeper who won $289 million from Monsanto in 2018 after a jury found the company failed to warn him about cancer risk. Kennedy was one of Johnson’s attorneys. He has stated publicly, as recently as early 2026, that he believes glyphosate causes cancer. He defended the liability protection order anyway. The fractures this created within the MAHA movement are real and ongoing.

Track Five: The Ruveon spinoff.

Days after the June 25 ruling, Bayer announced the separation of its glyphosate business into a new standalone entity called Ruveon. The timing was not coincidental. By ring-fencing the Roundup brand and all associated products into a separate subsidiary, Bayer insulates its core pharmaceutical and crop science divisions from whatever residual litigation survives the SCOTUS ruling. The claims that are not preempted, the types of suits the 2005 precedent left open, now land on Ruveon’s balance sheet rather than Bayer AG’s. Win the legal battle, spin off the remaining liability. The SCOTUS ruling and the spinoff are one sequenced strategy, not two separate corporate decisions.

Track Six: The Chinese glyphosate tariff petition.

Within days of the ruling, Bayer filed a trade petition seeking US duties on Chinese-made glyphosate. The petition was framed as protection against unfair competition. The effect, if granted, would be to hand Bayer dominant market position in the US glyphosate supply at precisely the moment its legal liability exposure has been minimized. The farmers who filed amicus briefs in Bayer’s favour during the Durnell case -- arguing glyphosate was essential to American agriculture -- are now the ones being squeezed by Bayer’s market protection play. The Amplification Principle question is worth asking directly: who actually benefited from the SCOTUS ruling? Not the farmers who defended the product in court. Not the 100,000 plaintiffs who lost their day in court. Bayer benefited. And Bayer moved immediately to consolidate that benefit into market dominance.

The Track That Failed

Not every track in the containment strategy succeeded. The pesticide industry had been pushing to include language in the 2026 Farm Bill giving the EPA sole regulatory oversight over pesticide labelling, a legislative codification of what the Durnell ruling accomplished judicially. The Republican-controlled House voted to strip it. The opposition came from an unexpected coalition: MAHA movement activists and progressive environmental groups finding themselves on the same side of a floor vote for entirely different reasons.

That failure matters for what it reveals. The six-track containment strategy is not invulnerable. When public attention coalesces around a specific legislative vehicle, in a specific window, with an unusual coalition, one track can be stopped. The Farm Bill provision was stopped. The lesson is not that the strategy failed. Five of six tracks succeeded, and the one that mattered most, the SCOTUS preemption argument, succeeded decisively. The lesson is that the strategy has seams, and those seams are where accountability efforts need to focus.

Beyond Roundup

The Durnell ruling does not apply only to glyphosate. It applies to any pesticide whose label has been approved under FIFRA. That means the preemption logic Kavanaugh established is now available to every manufacturer of every EPA-approved pesticide facing state failure-to-warn litigation.

Paraquat is the most immediate example. More than 6,000 plaintiffs have filed claims alleging paraquat exposure caused Parkinson’s disease. Syngenta, paraquat’s primary manufacturer, had already filed preemption motions in the paraquat MDL before Durnell was decided, anticipating the ruling. Those motions now have a seven-to-two Supreme Court decision behind them. Both plaintiff and defence attorneys in the paraquat litigation have told courts that the Durnell ruling could determine whether those 6,000 Parkinson’s claims survive.

Chlorpyrifos is a third pesticide now facing the identical preemption argument. Plaintiff firms are already recruiting Parkinson’s disease claimants for chlorpyrifos cases. The first lawsuit was filed in Pennsylvania days before the Durnell decision landed.

But the implications reach further than pesticides. In his majority opinion, Justice Kavanaugh referenced the preemption logic potentially applying to over-the-counter drugs, cosmetics, meat, poultry, eggs, and packaged foods, depending on how lower courts interpret the ruling. Each of those product categories has a federal regulatory approval process. Each of those processes could now function as a ceiling on state tort liability rather than a floor on safety requirements. The Durnell ruling is not a pesticide decision. It is a product liability restructuring event with implications across the consumer economy.

What Accountability Looks Like Now

The courthouse door is closed for failure-to-warn claims against Roundup. It is not the only door.

The most direct lever is the EPA review EPA promised in March 2026. The agency committed publicly to a comprehensive, transparent, and rigorous scientific review of glyphosate, including analysis of independent peer-reviewed research on potential cancer and developmental risks and expanded public access to underlying data. That commitment was made before the ruling that eliminated the legal pressure to deliver it. Whether EPA follows through, and whether the review honestly addresses the specific methodological failures the Ninth Circuit identified in 2022, is the live accountability question this series will continue to monitor. If EPA conducts a genuine review and reaches a different conclusion, the label changes. If the label changes, the preemption argument collapses for future plaintiffs. The ruling is not permanent. It is contingent on the EPA determination that underlies it.

Congressional oversight is a second lever. The EPA’s registration review process, its reliance on industry-submitted studies, its handling of the Ninth Circuit remand, and the specific methodological failures documented in the NRDC ruling are all subjects that fall within congressional oversight authority. Whether any committee pursues that oversight is a political question. The Farm Bill vote demonstrated that the unusual coalition capable of moving it exists. Whether it can be sustained and directed toward regulatory accountability is a different challenge.

State attorneys general retain authority the Durnell ruling did not touch. The preemption ruling bars state failure-to-warn tort claims. It does not bar state consumer protection enforcement, state public health regulation, state environmental monitoring, or state legislative action on pesticide use restrictions. Several states already ban or restrict glyphosate uses that federal law permits. That divergence can widen. It will require political will that the Modern Ag Alliance will continue to oppose, track by track, state by state.

International regulatory divergence is a fourth pressure point. The European Union has been moving toward tighter glyphosate restrictions for years. Canada’s Pest Management Regulatory Agency operates independently of EPA and has historically conducted its own reviews. If international regulatory bodies reach conclusions that diverge from EPA’s not likely determination, the scientific and political pressure on EPA to revisit its methodology increases. Bayer sells glyphosate products globally. A world in which the EU restricts glyphosate while the US shields manufacturers from liability is not a stable equilibrium.

And there is a fifth lever that is the most basic of all, and the one this series began with. The label.

If a product’s safety is genuinely unquestioned, manufacturers do not spend years and billions of dollars building legal, legislative, executive, and judicial shields against the consequences of that safety being examined. They compete on the evidence. The six-track containment strategy documented in this series is not the behaviour of a company confident in its science. It is the behaviour of a company managing a liability exposure it cannot resolve through science alone.

Consumers retain the right to ask questions the label does not answer. Farmers retain the right to choose inputs. Municipalities retain the right to restrict applications on public land. Journalists retain the right to publish what the primary documents show. None of those rights were closed by the Durnell ruling. The courtroom was the arena where evidence was tested, witness by witness, in front of twelve citizens. Losing that arena is not a small thing. But it is not the only arena.

Edwin Durnell

Edwin Durnell is still a Missouri man. He was still diagnosed with non-Hodgkin’s lymphoma. A Missouri jury still heard his evidence and still believed him. That did not change on June 25, 2026.

What changed is that the question his case raised -- did Monsanto have an obligation to warn him -- has been removed from the arena where it could be answered. Not because the answer is clear. Because the architecture built around the question made the question unanswerable in court.

This series began with a simple observation: the public was asked for decades to trust the science. The argument has shifted. It is no longer about the science. It is about whether the science can be litigated at all.

The question underneath that one has always been simpler. When a product causes harm, and a person is harmed, and a jury of that person’s peers finds the manufacturer failed in its duty to warn -- who decides whether that finding counts?

For now, the answer is: not a jury. Not a state court. A federal regulatory agency whose methodology a federal appeals court already found internally contradictory and legally unsupportable, and which restated its conclusion without correcting its methodology, and whose determination now functions as the permanent legal ceiling on what any American court can find about who was warned, and when, and whether it was enough.

That is the shield.

And that is what it was built to do.

Editor’s Notes

Primary sources for this series: Monsanto Co. v. Durnell, U.S. Supreme Court, decided June 25, 2026 (majority opinion by Kavanaugh, J.; concurrence by Thomas, J.; dissent by Jackson, J., joined by Gorsuch, J.); Natural Resources Defense Council v. U.S. Environmental Protection Agency, 38 F.4th 34 (9th Cir. 2022); EPA notification record for LARVIN Technical, EPA Reg. No. 264-343, Bayer CropScience, 2012; EPA public statement on glyphosate registration review, March 2026, as reported by The New Lede (Carey Gillam, March 27, 2026); Annals of Global Health, pesticide genotoxicity study, July 2026; International Agency for Research on Cancer, glyphosate classification as probable human carcinogen, 2015; Missouri circuit court settlement filings, February through July 2026; Kentucky General Assembly override record, 2026; Bayer AG corporate announcements on Ruveon spinoff, July 2026; US International Trade Commission petition filings, Bayer glyphosate antidumping case, June 2026.

Series note: The four parts of The Shield were developed sequentially as the legal proceedings unfolded. Part One was published before the Durnell ruling. Parts Two, Three, and Four were developed after the June 25, 2026 decision, using primary documents including the full Supreme Court opinion, the Ninth Circuit decision, and EPA regulatory filings. No claim in this series asserts definitively that glyphosate causes cancer in humans. The series reports what primary documents show about the legal, regulatory, and corporate architecture surrounding that question, accurately and at the correct epistemic level.

Ongoing monitoring: The Old Guardian will continue to monitor the EPA glyphosate registration review, paraquat and chlorpyrifos preemption proceedings, the Ruveon liability structure, and the $7.25 billion settlement fairness hearing scheduled for July 9, 2026.

The Old Guardian | theoldguardian.ca